Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Deferred Revenue (2016 - 2025)

Gyre Therapeutics has reported Current Deferred Revenue over the past 15 years, most recently at $14000.0 for Q4 2025.

  • Quarterly Current Deferred Revenue fell 77.05% to $14000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14000.0 through Dec 2025, down 77.05% year-over-year, with the annual reading at $14000.0 for FY2025, 77.05% down from the prior year.
  • Current Deferred Revenue was $14000.0 for Q4 2025 at Gyre Therapeutics, down from $58000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $2.0 million in Q2 2021 and troughed at $14000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $58000.0 (2025), against an average of $378923.1.
  • The largest YoY upside for Current Deferred Revenue was 517.58% in 2021 against a maximum downside of 88.4% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $230000.0 in 2021, then tumbled by 36.96% to $145000.0 in 2022, then plummeted by 73.1% to $39000.0 in 2023, then skyrocketed by 56.41% to $61000.0 in 2024, then tumbled by 77.05% to $14000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Current Deferred Revenue are $14000.0 (Q4 2025), $58000.0 (Q3 2025), and $28000.0 (Q1 2025).